Unique ID issued by UMIN | UMIN000015867 |
---|---|
Receipt number | R000018463 |
Scientific Title | Effect of GLP-1 receptor agonist in combination with insulin on abdominal fat in patients with type 2 diabetes trial |
Date of disclosure of the study information | 2014/12/15 |
Last modified on | 2016/12/08 07:56:04 |
Effect of GLP-1 receptor agonist in combination with insulin on abdominal fat in patients with type 2 diabetes trial
GLP-1 receptor agonist and abodominal fat in diabetes
Effect of GLP-1 receptor agonist in combination with insulin on abdominal fat in patients with type 2 diabetes trial
GLP-1 receptor agonist and abodominal fat in diabetes
Japan |
Patients with type 2 diabetes
Endocrinology and Metabolism |
Others
NO
To determine the effect of liraglutide on the abdominal fat accumulation and hepatic fat deposit in patients with type 2 diabetes
Efficacy
The change in visceral fat area 24 after administration of liraglutide
The change in liver attenuation index 24 after administration of liraglutide
Interventional
Parallel
Randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
Liraglutide 0.9 mg added to insulin treatment
insulin alone
20 | years-old | <= |
Not applicable |
Male and Female
Type 2 diabetic patients treated with insulin whose HbA1c levels are between 7 and 10% and BMI levels are> or = 25 kg/m2
Type 1 diabetes
Patients with allergy to incretin mimetics
Patients with interstitial pneumonia
Patints with liver chirrosis or renal failure
Patients who had experienced acute coronary syndrome or stroke or acute pancreatitis within 3 months prior to enrollment
Patients with malignant neoplasms
Patients who are alread treated with DPP4 inhibitors and/or GLP-1 receptor agonists.
Patients whose dosage of insulin has been changed by > 20 % within 3 months prior to enrollment
100
1st name | |
Middle name | |
Last name | Ryotaro Bouchi |
Tokyo Medical and Dental University
Departmet of Molecular Endocrinology and Metabolism
1-5-45 Yushima, Bunkyoku, Tokyo, Japan
03-3813-6111
bouchi.mem@tmd.ac.jp
1st name | |
Middle name | |
Last name | Ryotaro Bouchi |
Tokyo Medical and Dental University
Departmet of Molecular Endocrinology and Metabolism
1-5-45 Yushima, Bunkyoku, Tokyo, Japan
03-3813-6111
bouchi.mem@tmd.ac.jp
Tokyo Medical and Dental University
Tokyo Medical and Dental University
Self funding
NO
2014 | Year | 12 | Month | 15 | Day |
Published
https://www.ncbi.nlm.nih.gov/pubmed/27916783
Liraglutide treatment significantly reduced visceral fat area (VFA) at 24 weeks; whereas, subcutaneous fat are (SFA) was unchanged. albuminuria, liver attenuation index, and CRP levels were significantly reduced by liraglutide at 24 weeks and there was no difference in skeletal muscle index between the two groups.
Completed
2014 | Year | 12 | Month | 06 | Day |
2014 | Year | 12 | Month | 15 | Day |
2014 | Year | 12 | Month | 06 | Day |
2016 | Year | 12 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018463